A recent review published in JAMA authored by GCDTR’s Laura Jacobsen and Desmond Schatz, highlights key advances in understanding autoimmune mechanisms, early detection, and evolving treatment strategies. Key insights: • Type 1 diabetes accounts for 5%–10% of all diabetes cases and affects ~8.4 million people worldwide • 90%–95% of individuals have detectable islet autoantibodies at diagnosis, enabling early-stage identification before symptoms • Up to 44% of children and 23% of adults present with diabetic ketoacidosis at diagnosis • Continuous glucose monitoring combined with insulin pump therapy improves glycemic control and reduces hypoglycemia • Lifelong insulin therapy remains essential for disease management These insights highlight the importance of early detection, advancing technologies, and improved care strategies to reduce complications and improve outcomes in type 1 diabetes.
